XNAS
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.04 | -0.05 | -25.00% | $0 | ❌ Miss | +0.00% | -5.73% | -7.29% |
| 2026-03-20 | Q4 2025 | -0.04 | 1.08 | +2800.00% | $0 | ✅ Beat | +3.17% | +5.82% | +32.28% |
| 2025-11-10 |
| Q3 2025 |
| -0.29 |
| -0.38 |
| -31.03% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.53 | -0.58 | -9.43% | $0 | ❌ Miss | -7.43% | +8.24% | -27.16% |
| 2025-03-24 | Q4 2024 | -2.58 | -0.69 | +73.26% | $0 | ✅ Beat | -1.55% | -2.88% | +0.94% |
| 2024-08-12 | Q2 2024 | -2.93 | -3.32 | -13.31% | $0 | ❌ Miss | +1.09% | -1.37% | -0.55% |
| 2024-05-13 | Q1 2024 | -4.28 | -4.59 | -7.24% | $0 | ❌ Miss | +0.32% | -5.95% | -28.30% |
| 2024-03-26 | Q4 2023 | -5.10 | -3.75 | +26.47% | $0 | ✅ Beat | — | — | — |
Showing last 8 quarters.